These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 21622587

  • 1. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
    Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, INTENSITY study investigators.
    Eur Respir J; 2011 Oct; 38(4):797-803. PubMed ID: 21622587
    [Abstract] [Full Text] [Related]

  • 2. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec 15; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 4. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb 15; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 5. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D, INVIGORATE investigators.
    Lancet Respir Med; 2013 Sep 15; 1(7):524-33. PubMed ID: 24461613
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
    Mahler DA, Buhl R, Lawrence D, McBryan D.
    Pulm Pharmacol Ther; 2013 Jun 15; 26(3):348-55. PubMed ID: 23434446
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
    Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J.
    Respir Med; 2013 Jun 15; 107(6):854-62. PubMed ID: 23490224
    [Abstract] [Full Text] [Related]

  • 8. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B.
    Respir Med; 2012 Dec 15; 106(12):1715-21. PubMed ID: 23040786
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 15; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 10. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM, Williams J.
    Ther Adv Respir Dis; 2013 Feb 15; 7(1):25-37. PubMed ID: 23296242
    [Abstract] [Full Text] [Related]

  • 11. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul 15; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

  • 12. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M, Rossi A, Lawrence D, McBryan D.
    Respir Med; 2012 Dec 15; 106(12):1706-14. PubMed ID: 23031496
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.
    COPD; 2012 Dec 15; 9(6):629-36. PubMed ID: 23020650
    [Abstract] [Full Text] [Related]

  • 14. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
    Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B, INTRUST-1 and INTRUST-2 study investigators.
    Thorax; 2012 Sep 15; 67(9):781-8. PubMed ID: 22544891
    [Abstract] [Full Text] [Related]

  • 15. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW, Mahler DA, Gale R, Owen R, Kramer B.
    Respir Med; 2011 Jun 15; 105(6):892-9. PubMed ID: 21397482
    [Abstract] [Full Text] [Related]

  • 16. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.
    Eur Respir J; 2011 Feb 15; 37(2):273-9. PubMed ID: 20693243
    [Abstract] [Full Text] [Related]

  • 17. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J, Akitsu K.
    Pulm Pharmacol Ther; 2015 Feb 15; 30():128-33. PubMed ID: 25183687
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb 15; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun 15; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.
    Value Health; 2012 May 15; 15(3):524-33. PubMed ID: 22583463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.